Listar MD - Artículos por tipo "info:eu-repo/semantics/acceptedVersion"
Mostrando ítems 1-12 de 12
-
A Carboxylesterase 2 Gene Polymorphism as Predictor of Capecitabine on Response and Time to Progression
Ribelles, Nuria; López-Siles, J; Sánchez-Muñoz, Alfonso
; Sánchez, E; González, E; Sánchez, MJ; Carabantes, F; Sánchez- Rovira, P; Márquez, A; Dueñas, R; Sevilla, I; Alba-Conejo, Emilio[et al.] (Bentham Science Publishers Ltd, 2008)
Capecitabine is a drug that requires the consecutive action of three enzymes: carboxylesterase 2 (CES 2), cytidine deaminase (CDD), and thymidine phosphorylase (TP) for transformation into 5-fluorouracil (5FU). The ... -
A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study
Alba-Conejo, Emilio; Chacón, J. L.; Lluc, A.; Antón, A.; Estévez, L.; Cirauqui, B.; Carrasco, E.; Calvo, L.; Seguí, M.A.; Ribelles, Nuria; Álvarez, R.; Sánchez-Muñoz, Alfonso; Sánchez, R.; Lopez Garcia-Asenjo, J.A.; Rodriguez-Martin, C.; Escudero, M.J.; Albanell, J.[et al.] (Springer, 2012-10)
Abstract Chemotherapy remains as the only systemic treatment option available for basal-like breast cancer (BC) patients. Preclinical models and several phase II studies suggested that platinum salts are active drugs in ... -
Assessment of Procalcitonin as a Diagnostic and Prognostic Marker in Patients with Solid Tumors and Febrile Neutropenia
Jimeno, Antonio; García-Velasco, Adelaida; del Val, Olga; González-Billalabeitia, Enrique; Hernando, Susana; Hernández, Rosario; Sánchez-Muñoz, Alfonso; López-Martın, Ana; Durán, Ignacio; Robles, Luis; Corté-Funes, Hernán; Paz-Ares, Luis[et al.] (Wiley InterScience, 2004-03)
Cancer patients with fever and neutropenia currently are assessed on clinical grounds only. The current study prospectively evaluated the efficacy of baseline procalcitonin (PCT) in the detection of bacteremia and in the ... -
Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer
Sánchez-Muñoz, Alfonso; Mendiola, César; Pérez-Ruiz, Elisabeth; Rodríguez-Sánchez, César A.; Jurado, José Miguel; Alonso-Carrión, Lorenzo Javier; Ghanem, Ismael; Velasco, Guillermo de; Quero-Blanco, Cristina; Alba-Conejo, Emilio[et al.] (KARGER, 2010-11)
Aim: To retrospectively assess the efficacy and safety of bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Patients and Methods: Patients with recurrent ... -
Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study.
Pivot, X.; Verma, S.; Fallowfield, L.; Müller, M.; Lichinitser, M.; Jenkins, V.; Sánchez-Muñoz, Alfonso; Machackova, Z.; Osborne, S.; Gligorov, J.[et al.] (Elsevier, 2017-09-28)
Aim: To assess efficacy (event-free survival, EFS) and safety in patients followed up for 3 years in the PrefHer study (NCT01401166). Patients and methods: Post surgery and post chemotherapy in the (neo)adjuvant setting, ... -
Machine learning and natural language processing (NLP) approach to predict early progression to first-line treatment in real-world hormone receptor-positive (HRþ)/HER2-negative advanced breast cancer patients.
Ribelles, Nuria; Jerez-Aragonés, José Manuel; Rodríguez-Brazzarola, Pablo; Jiménez-Rodríguez, Begoña; Díaz-Redondo, Tamara; Mesa, Héctor; Márquez, Antonia; Sánchez-Muñoz, Alfonso; Pajares, Bella; Carabantes, Francisco; Bermejo-Pérez, María José; Villar, Ester; Domínguez-Recio, María Emilia; Saez-Lara, Enrique; Gálvez Carvajal, Laura; Godoy-Ortiz, Ana; Franco, Leónardo; Ruiz-Medina, Sofía; López, Irene; Alba-Conejo, Emilio[et al.] (Elsevier, 2021)
Background: CDK4/6 inhibitors plus endocrine therapies are the current standard of care in the first-line treatment of HRþ/HER2-negative metastatic breast cancer, but there are no well-established clinical or molecular ... -
Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes, and the subsequent clinical outcomes
Sánchez-Muñoz, Alfonso; Vicioso-Recio, Luis Prudencio; Santonja, Angela; Alvaréz, Martina; Plata-Fernández, Yéssica; Miramón, José; Zarcos, Irene; Ramírez-Tortosa, César; Montes-Torres, Julio; Jerez-Aragonés, José Manuel; De Luque, Vanessa; Llácer, Casilda; Fernández-De Sousa, C.E.; Pérez-Villa, Lidia; Alba-Conejo, Emilio[et al.] (Elsevier, 2018-02)
Male breast cancer is a rare disease that is still poorly understood. It is mainly classified by immunohistochemistry as a luminal disease. In this study, we assess for the first time the correlation between molecular ... -
Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes, and the subsequent clinical outcomes.
Sánchez-Muñoz, Alfonso; Vicioso-Recio, Luis Prudencio; Santonja, Ángela; Álvarez-Pérez, Martína; Plata-Fernández, Yéssica; Miramón, José; Zarcos, Irene; Ramírez-Tortosa, C.L.; Montes-Torres, Julio; Jérez, J.M.; De Luque, Vanessa; Llácer, Casilda; Fernández-De Sousa, C.E.; Pérez-Villa, Lidia; Alba-Conejo, Emilio[et al.] (Elsevier, 2017-09-22)
Male breast cancer is a rare disease that is still poorly understood. It is mainly classified by immunohistochemistry as a luminal disease. In this study, we assess for the first time the correlation between molecular ... -
Prognostic Significance of Venous Thromboembolic Events in Disseminated Germ Cell Cancer Patients.
González-Billalabeitia, Enrique; Castellano, Daniel; Sobrevilla, Nora; Guma, Josep; Hervás, David; Luengo, María I.; Aparicio, Jorge; Sánchez-Muñoz, Alfonso; Mellado, Begoña; Sáenz, Alberto; Valverde, Claudia; Fernández, Antonio; Margelí, Mireia; Durán, Ignacio; Fernández, Sara; Sastre, Javier; Ros, Silverio; Maroto, Pablo; Manneh, Ray; Cerezuela, Pablo; Carmona-Bayonas, Alberto; Ayala de la Peña, Francisco; Aguilar, José Luis; Rivera, Samuel; García del Muro, Xavier; Germá-Lluch, José Ramón[et al.] (Oxford Academic, 2017-01-26)
Background: Disseminated germ cell cancers are at high risk of developing thromboembolic complications. We evaluated the prognostic value of venous thromboembolic events (VTE) in disseminated germ cell cancer. Results: ... -
Risk-Adapted Treatment in Clinical Stage I Testicular Seminoma: The Third Spanish Germ Cell Cancer Group Study
Aparicio, Jorge; Maroto, Pablo; García del Muro, Xavier; Guma, Josep; Sánchez-Muñoz, Alfonso; Margelí, Mireia; Domenech, Montserrat; Bastús, Romá; Fernández, Antonio; Lopez-Brea, Marta; Terrassa, Josefa; Meana, Andrés; Martínez del Prado, Purificación; Sastre, Javier; Satrustegui, Juan J.; Girones, Regina; Robert, Lidia; Germa, José R.[et al.] (Editorial Roster. ASCO publications, 2011-10)
Purpose To confirm the efficacy of a risk-adapted treatment approach for patients with clinical stage I seminoma. The aim was to reduce both the risk of relapse and the proportion of patients receiving adjuvant chemotherapy ... -
Serum protein levels following surgery in breast cancer patients: A protein microarray approach
Pérez-Rivas, Luis G.; Jérez, J.M.; Fernández-De Sousa, C.E.; De Luque, Vanessa; Quero, C.; Pajares, Bella; Franco, L.; Sánchez-Muñoz, Alfonso; Ribelles, Nuria; Alba-Conejo, Emilio[et al.] (Spandidos Publications, 2012-07)
Surgery is the primary treatment for non-metastatic breast cancer. However, the risk of early recurrence remains after surgical removal of the primary tumor. Recurrence is suggested to result from hidden micrometastatic ... -
Targeted therapies in the treatment of germ cell tumors: The need for new approaches against “orphan” tumors
Sánchez-Muñoz, Alfonso; Jiménez-Rodríguez, Begoña; Navarro-Pérez, Víctor; Medina-Rodríguez, Laura; Llácer, Casilda; Vicioso-Recio, Luis Prudencio; Machuca, Javier; Alba-Conejo, Emilio[et al.] (Elsevier Ireland Ltd, 2012)
Germ cell tumors (GCTs) are a heterogeneous group of tumors that are highly clinically relevant to oncologists. GCTs are generally highly sensitive to cisplatin-based chemotherapy and represent a model for curable neoplasms. ...